MRNA Moderna Inc
Price (delayed)
$35.61
Market cap
$13.74B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.28
Enterprise value
$12.52B
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert
Highlights
The debt has declined by 46% since the previous quarter and by 42% year-on-year
The gross margin has soared by 74% YoY but it has contracted by 19% from the previous quarter
The net income has plunged by 60% from the previous quarter but it has grown by 24% YoY
MRNA's revenue has dropped by 53% year-on-year and by 36% since the previous quarter
MRNA's gross profit is down by 48% from the previous quarter and by 18% YoY
Key stats
What are the main financial stats of MRNA
Market
Valuations
Earnings
Shares outstanding
385.82M
Market cap
$13.74B
Enterprise value
$12.52B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
4.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
Revenue
$3.24B
Gross profit
$1.77B
Operating income
-$3.95B
Net income
-$3.56B
EBIT
-$3.61B
EBITDA
-$3.42B
Free cash flow
-$4.06B
Per share
Balance sheet
Liquidity
EPS
-$9.28
EPS diluted
-$9.28
Free cash flow per share
-$10.56
Book value per share
$28.33
Revenue per share
$8.43
TBVPS
$36.83
Total assets
$14.14B
Total liabilities
$3.24B
Debt
$710M
Equity
$10.9B
Working capital
$5.89B
Debt to equity
0.07
Current ratio
3.67
Quick ratio
3.35
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-105.6%
Gross margin
54.8%
Net margin
-110%
Operating margin
-121.9%
Return on assets
-22.8%
Return on equity
-30.1%
Return on invested capital
-29.1%
Return on capital employed
-30.2%
Return on sales
-111.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
3.82%
1 week
15.02%
1 month
9.23%
1 year
-64.2%
YTD
-14.36%
QTD
-14.36%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$3.24B
Gross profit
$1.77B
Operating income
-$3.95B
Net income
-$3.56B
Gross margin
54.8%
Net margin
-110%
The net margin has dropped by 151% since the previous quarter and by 60% year-on-year
Moderna's operating margin has shrunk by 130% QoQ and by 97% YoY
The gross margin has soared by 74% YoY but it has contracted by 19% from the previous quarter
The net income has plunged by 60% from the previous quarter but it has grown by 24% YoY
Growth
What is Moderna's growth rate over time
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
1.26
P/S
4.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
The company's EPS has shrunk by 60% QoQ but it rose by 25% YoY
MRNA's P/B is 80% below its 5-year quarterly average of 6.4 and 53% below its last 4 quarters average of 2.7
The equity is down by 21% YoY and by 9% QoQ
The stock's P/S is 88% below its 5-year quarterly average of 35.3 and 37% below its last 4 quarters average of 6.7
MRNA's revenue has dropped by 53% year-on-year and by 36% since the previous quarter
Efficiency
How efficient is Moderna business performance
The company's return on sales has shrunk by 141% QoQ and by 94% YoY
Moderna's ROA has plunged by 71% from the previous quarter
MRNA's return on equity has dropped by 70% since the previous quarter
The ROIC has plunged by 63% from the previous quarter and by 13% YoY
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
Moderna's total liabilities has decreased by 29% YoY and by 16% QoQ
Moderna's total assets has decreased by 23% YoY and by 11% from the previous quarter
The debt is 93% smaller than the equity
The debt has declined by 46% since the previous quarter and by 42% year-on-year
The company's debt to equity fell by 36% QoQ and by 22% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.